Faculty of Medicine Chulalongkorn University
Bangkok, Thailand
Location status: Recruiting
Recruiting
NCT Number: NCT07055009
Multi-centred Clinico-genetic Study of Actinic Prurigo in Thailand
This research project investigates the clinical and genetic associations of Actinic Prurigo (AP) in the Thai population. As a rare chronic photodermatosis, AP has been observed to occur more frequently in individuals with certain genetic predispositions, particularly specific Human Leukocyte Antigen (HLA) types. Previous studies have suggested variations in clinical presentation and HLA allele distributions between Asian and Western populations.
The primary aim is to explore the relationship between clinical manifestations of AP and genetic profiles, including HLA typing, among Thai individuals. Additionally, the study seeks to examine whether different HLA types are associated with varying responses to treatment.
The study design is a cross-sectional comparative study, involving both AP patients and age-matched healthy controls. Given the rarity of the condition, patient recruitment will be conducted across four collaborating institutions:
King Chulalongkorn Memorial Hospital Siriraj Hospital Institute of Dermatology
Recruiting
Interested in participating?
Request InfoKey information
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Thai ethnicity
- Diagnosed with Actinic Prurigo (AP) according to the diagnostic criteria defined for this study
- Mentally competent, able to communicate, and able to read Thai.
- Participants receiving Thalidomide treatment must use two simultaneous methods of contraception, starting at least 4 weeks prior to initiating the medication and continuing throughout the treatment period and for at least 4 weeks after discontinuation.
Exclusion criteria
- History and physical examination findings suggestive of other photodermatoses such as Lupus erythematosus, Porphyria, or Polymorphous Light Eruption, among others.
- Elevated Epstein-Barr Virus (EBV) viral load detected in blood testing (EBV viral load will be tested in all participants).
- Low Minimal Erythema Dose (MED) to UVB radiation as the only abnormal finding.
Treatment and study plan
Targeted long-read HLA sequencing
Diagnostic TestGenetic study
Other names: Short-read whole genome sequencing
RNA extraction
OtherNanostring technology, Seattle
Full Skin examination
OtherSkin and mucosa examination
Primary outcomes
-
Targeted long-read HLA sequencing
Time frame: through study completion, an average of 1 year
Correlation between the occurrence of Actinic Prurigo (AP), its clinical manifestations, and genetic factors-including HLA types-in individuals of Thai ancestry.
Secondary outcomes
-
Short-read whole genome sequencing (WGS)
Time frame: through study completion, an average of 1 year
Correlation between the occurrence of Actinic Prurigo (AP), its clinical manifestations, and genetic factors-including short-read whole genome sequencing (WGS)-in individuals of Thai ancestry.
-
Immunology study
Time frame: through study completion, an average of 1 year
Correlation between the occurrence of Actinic Prurigo (AP), its clinical manifestations, and immunological factors in individuals of Thai ancestry, measured by RNA extraction and gene expression analysis.
Study contacts
Contact information is provided by the study sponsor or research team.
Einapak Boontaveeyuwat, MD
CONTACT
Kittima Leklad
CONTACT
Sponsors and collaborators
Lead sponsor
Chulalongkorn University
Other
Collaborators
- Health Systems Research Institute,Thailand
Registry information
Important dates
- Study start
- 2025
- Primary completion
- 2026
- Study completion
- 2026
- First posted
- Jul 8, 2025
- Registry last updated
- May 12, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.